Axsome Therapeutics (AXSM) said Monday it received feedback from the US Food and Drug Administration supporting a submission of its drug for Alzheimer's disease agitation for approval.
Meeting minutes from the company's pre-new drug application huddle with the FDA indicated that the company's regulatory data package for AXS-05 would support a supplemental new drug application, the company said.
The company said it anticipates making such a submission in Q3.
The treatment holds the FDA's breakthrough therapy designation and will be eligible for a priority review, Axsome noted.
Price: 129.00, Change: +1.46, Percent Change: +1.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。